Vivodyne, a biotech startup, is tackling the limitations of current AI drug-discovery methods by developing a machine that can generate causal biological data, which is currently lacking in the industry.
Key Insights
Vivodyne's HIVE machines can grow 20 kinds of human tissue and autonomously dose and monitor them, providing a more accurate representation of human biology than traditional methods. The company has raised nearly $80 million in funding and is working with major pharma companies to accelerate drug discovery, bringing new hope to the field of cancer research.
